AAP
ATYR

Ardsley Advisory Partners’s aTyr Pharma ATYR Stock Holding History

Ardsley Advisory Partners’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-20,000
Closed -$65K – 196
2020
Q3 		$65K Buy
+20,000
New +$82.1K 0.01% 141

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Ardsley Advisory Partners's ATYR Position: Q4 2020 in Review

Ardsley Advisory Partners sold out of aTyr Pharma (ATYR) in Q4 2020, closing a stake of 20,000 shares — an estimated $65K sold.

Ardsley Advisory Partners first reported a position in ATYR in Q3 2020 and held it in 1 quarter. The position peaked at $65K in Q3 2020. 23 funds tracked by Wall St. Rank hold ATYR as of Q4 2020.

  • Ardsley Advisory Partners reported no remaining aTyr Pharma position as of Q4 2020 after selling out during the quarter.
  • Ardsley Advisory Partners sold 20,000 aTyr Pharma shares in Q4 2020, an estimated $65K.
  • Ardsley Advisory Partners first reported a position in aTyr Pharma in Q3 2020 and held it in 1 quarter.
  • Ardsley Advisory Partners's aTyr Pharma position peaked at $65K in Q3 2020.
  • 23 funds tracked by Wall St. Rank held aTyr Pharma as of Q4 2020.

Based on Ardsley Advisory Partners's 13F filing for Q4 2020, filed 16 Feb 2021.